GoAI
Get started
ImageneBio Inc logo

ImageneBio Inc

IMA

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$5.60

+$0.09 · +1.63%

Aug 24, 10:16 AM ET

IMA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

31

Expensive

Momentum

38

Weakening

Sentiment

46

Mixed

Risk resilience

44

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Kristin Yarema
Listed since
Feb 27, 1998
Employees
18

Market position

Volume
3.88K
0.18× average
Average volume
21.17K
Average daily volume
Market cap
63.16M USD
Beta
0.76
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.07×
P/B (TTM)
0.64×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.01×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends703%-1755%-4213%-6671%Gross margin, FY2021: -52.03%Gross margin, FY2022: -311.84%Gross margin, FY2023: 88.86%Gross margin, FY2024: 56.40%Gross margin, FY2025: -29.13%Operating margin, FY2021: -110.18%Operating margin, FY2022: -453.99%Operating margin, FY2023: -823.33%Operating margin, FY2024: -1057.14%Operating margin, FY2025: -6056.38%Net margin, FY2021: -110.10%Net margin, FY2022: -440.29%Net margin, FY2023: -744.17%Net margin, FY2024: -1044.80%Net margin, FY2025: -5668.63%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -52.03%. Gross margin FY2022 -311.84%. Gross margin FY2023 88.86%. Gross margin FY2024 56.40%. Gross margin FY2025 -29.13%. Operating margin FY2021 -110.18%. Operating margin FY2022 -453.99%. Operating margin FY2023 -823.33%. Operating margin FY2024 -1057.14%. Operating margin FY2025 -6056.38%. Net margin FY2021 -110.10%. Net margin FY2022 -440.29%. Net margin FY2023 -744.17%. Net margin FY2024 -1044.80%. Net margin FY2025 -5668.63%.

Income trends

Revenue

800K USD-77.14%

Operating income

−48.45M USD-30.95%

Net income

−45.35M USD-24.01%
Income trends across reported periods41.63M USD−935.6K USD−43.5M USD−86.06M USDRevenue, FY2021: 30.99M USDRevenue, FY2022: 15.62M USDRevenue, FY2023: 9.16M USDRevenue, FY2024: 3.5M USDRevenue, FY2025: 800K USDOperating income, FY2021: −34.14M USDOperating income, FY2022: −70.9M USDOperating income, FY2023: −75.42M USDOperating income, FY2024: −37M USDOperating income, FY2025: −48.45M USDNet income, FY2021: −34.12M USDNet income, FY2022: −68.77M USDNet income, FY2023: −68.17M USDNet income, FY2024: −36.57M USDNet income, FY2025: −45.35M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 30.99M USD. Revenue FY2022 15.62M USD. Revenue FY2023 9.16M USD. Revenue FY2024 3.5M USD. Revenue FY2025 800K USD. Operating income FY2021 −34.14M USD. Operating income FY2022 −70.9M USD. Operating income FY2023 −75.42M USD. Operating income FY2024 −37M USD. Operating income FY2025 −48.45M USD. Net income FY2021 −34.12M USD. Net income FY2022 −68.77M USD. Net income FY2023 −68.17M USD. Net income FY2024 −36.57M USD. Net income FY2025 −45.35M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue800K USD3.5M USD9.16M USD15.62M USD30.99M USD
Cost of goods sold1.03M USD1.53M USD1.02M USD64.32M USD47.11M USD
Gross profit−233K USD1.97M USD8.14M USD−48.7M USD−16.12M USD
Research and development28.53M USD32.11M USD59.65M USD64.32M USD47.11M USD
Selling, general, and administrative20.73M USD8.39M USD24.93M USD22.2M USD18.02M USD
Operating expenses48.22M USD38.97M USD83.56M USD22.2M USD18.02M USD
Interest income2.04M USD7.37M USD7.11M USD2.15M USD23K USD
Depreciation and amortization1.03M USD1.53M USD1.02M USD751K USD544K USD
Operating income−48.45M USD−37M USD−75.42M USD−70.9M USD−34.14M USD
Net income−45.35M USD−36.57M USD−68.17M USD−68.77M USD−34.12M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+9.51%
11 comparable reports
Latest EPS result
-0.63
Estimate -0.98 · Beat by 35.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.05-1.08-2.11-3.14Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 6, 2025: actual -0.18, estimate -0.23, surprise +21.74%, Beat. Q2 2025, reported May 8, 2025: actual -0.18, estimate -0.21, surprise +14.29%, Beat. Q3 2025, reported Jul 24, 2025: actual -0.06, estimate -0.14, surprise +57.14%, Beat. Q4 2025, reported Nov 12, 2025: actual -2.91, estimate -1.47, surprise -97.96%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.62, estimate -1.45, surprise +57.24%, Beat. Q2 2026, reported May 7, 2026: actual -0.95, estimate -0.7, surprise -35.71%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.63, estimate -0.977, surprise +35.50%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.76, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.67M1.54M401.14K-735.08KQ1 '24MissQ2 '24EstimateQ1 '25EstimateQ2 '25No estimateQ3 '25No estimate
Q1 2024, reported Mar 12, 2024: actual 658K USD, estimate 2.44M USD, surprise -73.02%, Miss. Q2 2024, reported May 13, 2024: actual —, estimate 2.33M USD, surprise —, Comparison unavailable. Q1 2025, reported Mar 6, 2025: actual —, estimate 875K USD, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 800K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Jul 24, 2025: actual -500K USD, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$1.33

76.25% downside
Past 12 months12-month forecastHigh $1.33Average $1.33Low $1.33

IMA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

Continue in GoAI

Research IMA

research.disclaimer